| Q88523381 | A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole |
| Q90254018 | A Prospective Real-World Study of the Impact of an Antifungal Stewardship Program in a Tertiary Respiratory-Medicine Setting |
| Q28388755 | A case report of inhalation anthrax acquired naturally |
| Q36265747 | A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring |
| Q91777235 | A clinical approach to respiratory disease in patients with hematological malignancy, with a focus on respiratory infection |
| Q39653780 | A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy. |
| Q36308059 | A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers |
| Q64120981 | A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia |
| Q38483558 | A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis |
| Q41907424 | A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid |
| Q33385491 | A risk profile for invasive aspergillosis in liver transplant recipients |
| Q40039262 | Acute myeloid leukemia and the infectious diseases consultant |
| Q53127302 | Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. |
| Q46763769 | Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient |
| Q46788198 | Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q34452574 | Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation |
| Q52936136 | Analysis of the clinical features of invasive bronchopulmonary aspergillosis. |
| Q37159568 | Antifungal agents--clinical pharmacokinetics and drug interactions |
| Q34400255 | Antifungal clinical trials and guidelines: what we know and do not know |
| Q37816399 | Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients |
| Q37866827 | Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? |
| Q38944746 | Antifungal stewardship considerations for adults and pediatrics |
| Q37310029 | Antifungal therapeutic drug monitoring: established and emerging indications |
| Q37161793 | Antifungal therapies in the intensive care unit |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q36591360 | Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection |
| Q57549163 | Antimicrobial Agents |
| Q37048679 | Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact |
| Q37772501 | Approaches to the early treatment of invasive fungal infection |
| Q47645142 | Aspergillosis in Chronic Granulomatous Disease. |
| Q39987609 | Aspergillosis in hematopoietic stem cell transplant recipients: risk factors, prophylaxis, and treatment |
| Q42272291 | Aspergillosis in solid organ transplantation |
| Q37101166 | Aspergillus tracheobronchitis causing subtotal tracheal stenosis in a liver transplant recipient |
| Q38406393 | Azole antifungals: 35 years of invasive fungal infection management |
| Q40435009 | Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis |
| Q46567838 | Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis |
| Q80778520 | Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia |
| Q52593361 | CYP51 as drug targets for fungi and protozoan parasites: past, present and future. |
| Q37159584 | Caspofungin for treatment of invasive aspergillus infections. |
| Q93078617 | Central Nervous System Infections Due to Aspergillus and Other Hyaline Molds |
| Q36920608 | Changing epidemiology of rare mould infections: implications for therapy |
| Q37081683 | Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients |
| Q58701142 | Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections |
| Q38871233 | Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections. |
| Q34546811 | Clinical hepatotoxicity associated with antifungal agents |
| Q42413286 | Clinical pharmacodynamics and pharmacokinetics of the antifungal extended‐spectrum triazole posaconazole: an overview |
| Q35026481 | Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. |
| Q37000091 | Combination antifungal therapy for the treatment of invasive yeast and mold infections |
| Q40841377 | Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections |
| Q39026820 | Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre |
| Q37775500 | Conazoles. |
| Q37373785 | Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: how firm is the Aspergillus diagnosis? |
| Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
| Q38284463 | Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
| Q45861947 | Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options |
| Q37079099 | Current and future therapeutic options in the management of invasive aspergillosis |
| Q37402524 | Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients |
| Q37908856 | Current concepts in antifungal pharmacology |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q39269082 | Cutaneous Toxicities From Transplantation-Related Medications |
| Q104492457 | Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance |
| Q37164085 | Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria |
| Q46273412 | Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction |
| Q37813420 | Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections |
| Q37889382 | Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy |
| Q36862446 | Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). |
| Q39443748 | Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. |
| Q36111766 | Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada |
| Q35607672 | Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation |
| Q41767156 | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay |
| Q48202863 | Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers |
| Q37409875 | Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers |
| Q35635971 | Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers |
| Q37944001 | Efficacy and safety of current drug therapies for invasive aspergillosis |
| Q40062960 | Efficacy and safety of posaconazole in hematopoietic stem cell transplantation patients with invasive fungal disease |
| Q41175826 | Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia |
| Q37779496 | Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort |
| Q42109334 | Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani |
| Q51042801 | Environmental fungicides and triazole resistance in Aspergillus. |
| Q35089772 | Epidemiology and treatment approaches in management of invasive fungal infections |
| Q38135904 | Epidemiology and treatment of mucormycosis |
| Q40112567 | Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High-Risk for Fungal Infections |
| Q36076106 | Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration |
| Q47098888 | Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. |
| Q37761047 | Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma |
| Q90577176 | Extrapolating Antifungal Animal Data to Humans - Is it reliable? |
| Q33867013 | Factors associated with mortality in transplant patients with invasive aspergillosis |
| Q35065903 | Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole |
| Q41354303 | Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis. |
| Q34427584 | Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation |
| Q47580986 | Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study |
| Q37739908 | Fungal infections after hematopoietic stem cell transplantation |
| Q38202571 | Fungal infections in cancer patients |
| Q37058527 | Fungal infections in intensive care unit: challenges in diagnosis and management |
| Q36841586 | Fungal infections in primary immunodeficiencies |
| Q51184875 | Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. |
| Q33896940 | Fungal infections in transplant and oncology patients |
| Q38252946 | Fungal infections of the skin and nail: new treatment options. |
| Q37060071 | Fungal rhinosinusitis and imaging modalities |
| Q37123394 | Fungicidal versus Fungistatic: what's in a word? |
| Q37904672 | Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. |
| Q64982266 | Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. |
| Q39755518 | High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient |
| Q42314358 | Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels. |
| Q80383094 | Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications |
| Q42939581 | Impact of glucuronide interferences on therapeutic drug monitoring of posaconazole by tandem mass spectrometry. |
| Q37263430 | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates |
| Q92872635 | Implications for IV posaconazole dosing in the era of obesity |
| Q40202912 | In Vivo 11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia |
| Q42950831 | In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan |
| Q45238820 | In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. |
| Q63379731 | Inadequate diagnostics: the case to move beyond the bacilli for detection of meningitis due to Mycobacterium tuberculosis |
| Q30235457 | Intensive care medicine research agenda on invasive fungal infection in critically ill patients |
| Q58775551 | Invasive Aspergillosis in Children: Update on Current Guidelines |
| Q64229013 | Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment |
| Q37954958 | Invasive aspergillosis in children with acquired immunodeficiencies |
| Q37854719 | Invasive aspergillosis in children with hematological malignancies |
| Q33800526 | Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study |
| Q28306909 | Invasive aspergillosis in the intensive care unit |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q38110850 | Invasive candidiasis: update on current pharmacotherapy options and future perspectives |
| Q34288593 | Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational s |
| Q38151663 | Invasive fungal infections |
| Q34461693 | Invasive fungal infections in solid organ transplant recipients |
| Q37306108 | Invasive opportunistic mycoses: clinical trials review, 2007-2008. |
| Q88595472 | Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials |
| Q40865179 | Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial |
| Q34900399 | Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections |
| Q37916824 | Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients |
| Q92707809 | Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis |
| Q37345694 | Lung infections after cancer chemotherapy |
| Q37202860 | Management of fungal infections following allogeneic stem cell transplantation |
| Q36087577 | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients |
| Q36364013 | Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. |
| Q38802008 | Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. |
| Q34309603 | Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and |
| Q37364295 | New and investigational triazole agents for the treatment of invasive fungal infections |
| Q38797864 | New facets of antifungal therapy |
| Q37579222 | New generation azole antifungals in clinical investigation |
| Q46112222 | Novel Approaches to Antifungal Therapy |
| Q46840248 | Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin |
| Q37786165 | Opportunistic Fungi: A View to the Future |
| Q50519900 | Optimising absorption of posaconazole. |
| Q37552818 | Other HIV-associated pneumonias |
| Q35584615 | Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles |
| Q49612998 | Pediatric Invasive Aspergillosis |
| Q37790947 | Pediatric Invasive Aspergillosis |
| Q46583730 | Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. |
| Q40083822 | Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease |
| Q37756116 | Pharmacokinetic/pharmacodynamic profile of posaconazole |
| Q37115829 | Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers |
| Q38193337 | Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. |
| Q34754956 | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy |
| Q26771180 | Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections |
| Q41993016 | Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. |
| Q35105840 | Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects |
| Q55236793 | Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q35941414 | Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. |
| Q46879963 | Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease |
| Q46341880 | Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. |
| Q37247780 | Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers |
| Q38813173 | Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration |
| Q35959476 | Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature |
| Q33798313 | Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. |
| Q34299092 | Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia |
| Q40892430 | Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. |
| Q80066469 | Posaconazole |
| Q93480679 | Posaconazole (Noxafil), an Extended-Spectrum Oral Triazole Antifungal Agent |
| Q37203849 | Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels |
| Q40337289 | Posaconazole Plasma Monitoring in Immunocompromised Children |
| Q36424973 | Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. |
| Q42285675 | Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. |
| Q38899363 | Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole |
| Q44162406 | Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation |
| Q46340631 | Posaconazole concentrations in the central nervous system |
| Q36018743 | Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring |
| Q91916135 | Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis |
| Q42572410 | Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration |
| Q40827808 | Posaconazole in lung transplant recipients: use, tolerability, and efficacy |
| Q37052755 | Posaconazole in the management of refractory invasive fungal infections |
| Q35732778 | Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole |
| Q48118247 | Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients |
| Q36505539 | Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis |
| Q43506893 | Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis |
| Q35647678 | Posaconazole plasma concentrations in juvenile patients with invasive fungal infection |
| Q40517272 | Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. |
| Q38237895 | Posaconazole salvage treatment for invasive fungal infection |
| Q43056048 | Posaconazole salvage treatment in paediatric patients: a multicentre survey |
| Q34737174 | Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy |
| Q33798286 | Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. |
| Q92402338 | Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations |
| Q35262607 | Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. |
| Q43128336 | Posaconazole therapeutic drug monitoring: a reference laboratory experience |
| Q37094649 | Posaconazole treatment in Korea: single-center experience over 5 years |
| Q37404840 | Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update |
| Q41848545 | Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections |
| Q36828159 | Posaconazole: a new broad-spectrum antifungal agent |
| Q33382991 | Posaconazole: a new oral antifungal agent with an expanded spectrum of activity |
| Q40188974 | Posaconazole: a next-generation triazole antifungal |
| Q38321383 | Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections |
| Q28291282 | Posaconazole: an oral triazole with an extended spectrum of activity |
| Q37901534 | Posaconazole: when and how? The clinician's view |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q37327107 | Present situation in the treatment of invasive fungal infection |
| Q41688288 | Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment |
| Q37344532 | Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. |
| Q46802771 | Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection |
| Q35959480 | Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature |
| Q91876531 | Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans |
| Q43754399 | Pulmonary and other aspergilloses in patients in the intensive care unit |
| Q40337647 | Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry |
| Q24642450 | Recent advances in the management of mucormycosis: from bench to bedside |
| Q39767419 | Reflections on the approach to treatment of a mycologic disaster |
| Q88376520 | Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole |
| Q41915726 | Refractory invasive aspergillosis controlled with posaconazole and pulmonary surgery in a patient with chronic granulomatous disease: case report |
| Q35065721 | Relevance of timing for determination of posaconazole plasma concentrations |
| Q40043031 | Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience. |
| Q35860057 | Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension |
| Q40109740 | Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation |
| Q38341595 | Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole |
| Q37055215 | Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent |
| Q39659834 | Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. |
| Q47697145 | Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations. |
| Q33549666 | SREB, a GATA transcription factor that directs disparate fates in Blastomyces dermatitidis including morphogenesis and siderophore biosynthesis |
| Q38077591 | Safety of posaconazole |
| Q37662650 | Safety of triazole antifungal drugs in patients with cancer |
| Q42078949 | Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. |
| Q37327086 | Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action |
| Q36171677 | Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension |
| Q34362577 | Sixty-year-old man with slowly expanding nodular plaque on the thigh |
| Q33826421 | Skin concentrations and pharmacokinetics of posaconazole after oral administration |
| Q34108650 | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients |
| Q42965419 | Successful management of invasive pulmonary nocardiosis and aspergillosis in a patient with T-cell lymphoma: a case report. |
| Q34596950 | Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity |
| Q40078596 | Synergistic drug combination effectively blocks Ebola virus infection |
| Q37331953 | The enzymatic basis of drug-drug interactions with systemic triazole antifungals. |
| Q90149459 | The potency of luliconazole against clinical and environmental Aspergillus nigri complex |
| Q42751535 | The role of second-generation antifungal triazoles for treatment of the endemic mycoses. |
| Q93085278 | Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients |
| Q26746016 | Therapeutic Drug Monitoring of Posaconazole: an Update |
| Q37688257 | Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology |
| Q38738090 | Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q38790740 | Therapeutic drug monitoring of anti-infective agents in critically ill patients |
| Q36276966 | Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease |
| Q84193187 | Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake |
| Q34108484 | Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method |
| Q36396203 | Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome |
| Q39041116 | Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review |
| Q37450660 | Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults |
| Q37833074 | Therapeutic drug monitoring of voriconazole and posaconazole |
| Q38140015 | Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. |
| Q90672647 | Therapy of Mucormycosis |
| Q58765898 | Treatment of Aspergillosis |
| Q89240837 | Treatment of Aspergillus fumigatus infection with posaconazole delayed-release tablets |
| Q40323166 | Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs |
| Q91942866 | Treatment of Posaconazole-Induced Peripheral Neuropathy With Methylprednisolone and Magnesium Infusions: A Case Report |
| Q47697132 | Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence |
| Q37469829 | Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
| Q37863921 | Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B? |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
| Q40762430 | Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome. |
| Q28553573 | Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model |
| Q34309527 | Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing |
| Q34596750 | Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. |
| Q43191432 | Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine |
| Q37785548 | Updated guidelines for managing fungal diseases in hematology patients |
| Q90623202 | Use of Antifungals and Outcomes Among Inpatients at Risk of Invasive Aspergillosis or Mucormycosis in the USA: A Retrospective Cohort Study |
| Q41457024 | Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis |
| Q37810083 | Use of posaconazole in the treatment of invasive fungal infections |
| Q90131095 | Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension |
| Q54243380 | Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. |
| Q38890514 | Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection |
| Q38073201 | Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review |
| Q46826187 | Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes |
| Q37141697 | Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients |
| Q40082257 | Voriconazole-refractory invasive aspergillosis |
| Q44420165 | What is the role of therapeutic drug monitoring in antifungal therapy? |
| Q42578023 | What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? |
| Q37374949 | Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods |
| Q42625550 | Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution |
| Q83392396 | [Antifungal therapy update: new drugs and medical uses] |
| Q46020723 | [Keratomycosis: diagnosis and therapy]. |
| Q84149141 | [Pharmacokinetics and pharmacodynamics of antifungal drugs in children] |